Based on this amendment, the territories at the mercy of the License Contract have been transformed to reflect that Astellas will lead to all regulatory filings and can solely commercialize and assume full responsibility for manufacturing isavuconazole in the U.S. And Canada. Basilea assumes complete privileges to isavuconazole in the rest of the world in return for waiving its to co-promote the product in the U.S. And Canada. The original agreement was executed in February 2010. Under the amended agreement, the submission of the New Drug Program and potential approval in the U.S. Will still be at the mercy of the payment of a development milestone by Astellas. Furthermore, the conditions regarding product sales milestone payments have already been changed.During the first one fourth of fiscal year 2013 when compared to first quarter of fiscal yr 2012. Knee product sales decreased 1 percent worldwide through the first one fourth and increased 1 percent in the U.S. Hip sales decreased 1 percent worldwide through the first quarter and elevated 1 percent in the U.S. S.E.T. Product sales increased 56 percent worldwide to $127.3 million through the first quarter, and elevated 52 percent in the U.S. Excluding the Trauma Acquisition, S.E.T.